IN VIVO PHOTOACOUSTIC AND PHOTOTHERMAL NANO-THERANOSTICS OF BIOFILMS
A device and methods for the non-invasive manipulation and detection of target objects such as cells, pathogens, microparticles, and nanoparticles in vivo using an external magnetic field are described. In one aspect, a device and method for capturing and detecting intrinsically magnetic target objects or target objects labeled with at least one magnetic particle within the area of interest using an in vivo flow cytometer are described.
1 . A method for detecting a biofilm within a subject in vivo, comprising:
contacting at least one functionalized PA contrast agent with the biofilm, wherein the at least one functionalized PA contrast agent comprises at least one PA contrast agent linked to at least one targeting agent;
directing at least one laser pulse into an area of interest containing the biofilm;
detecting at least one photoacoustic signal emitted by the at least one PA contrast agent bound to a targeting moiety on the biofilm via the targeting agent; and,
analyzing the at least one detected photoacoustic signal to indicate the presence of the biofilm.
2 . The method of claim 1 , wherein the at least one contrast agent is selected from the group consisting of: gold nanospheres, gold nanoshells, gold nanorods, gold cages, carbon nanoparticles, perfluorocarbon nanoparticles, carbon nanotubes, spectrally tunable golden carbon nanotubes, carbon nanohorns, magnetic nanoparticles, silica-coated magnetic nanoparticles, quantum dots, binary gold-carbon nanotube nanoparticles, multilayer nanoparticles, clustered nanoparticles, liposomes, micelles, and microbubbles.
3 . The method of claim 1 , wherein the at least one targeting agent comprises an antibody, a protein, a ligand for one or more specific cell receptors, a receptor, a peptide, or a wheat germ agglutinin.
4 . The method of claim 3 , wherein the at least one targeting agent is selected from the group consisting of antibodies to protein A receptors of Staphylococcus aureus , antibodies to a lipoprotein, ligands to polysaccharide and siderophore receptors of a bacteria, and an antibody specific for a protein highly expressed in a bacteria but absent in mammalian cells.
5 . The method of claim 4 , wherein the bacteria is chosen from: Clostridium difficile ; Carbapenem-resistant Enterobacteriaceae (ORE); drug-resistant Neisseria gonorrhoeae ; multidrug-resistant Acinetobacter ; drug-resistant Campylobacter ; extended spectrum β-lactamase producing Enterobacteriaceae (ESBLs); vancomycin-resistant Enterococcus (VRE); multidrug-resistant Pseudomonas aeruginosa ; drug-resistant non-typhoidal Salmonella ; drug-resistant Salmonella typhi ; drug-resistant Shigella ; methicillin-resistant Staphylococcus aureus (MRSA); drug-resistant Streptococcus pneumoniae ; drug-resistant tuberculosis; vancomycin-resistant Staphylococcus aureus (MRSA); erythromycin-resistant Group A Streptococcus ; clindamycin-resistant Group B Streptococcus; Staphylococcus epidermis ; and any combination thereof.
6 . The method of claim 1 , wherein the laser pulse is released from outside the subject.
7 . The method of claim 1 , wherein the laser pulse is released through an optical fiber situated within the subject.
8 . The method of claim 1 , wherein the at least one functionalized PA contrast agent is contacted with the biofilm by injection at an injection site of the subject.
9 . A method for selectively destroying a biofilm within a subject in vivo, comprising:
contacting at least one functionalized PA contrast agent with the biofilm, wherein the at least one functionalized PA contrast agent comprises at least one PA contrast agent linked to at least one targeting agent;
directing at least one detection laser pulse into an area of interest containing the biofilm;
detecting at least one photoacoustic signal emitted by the at least one PA contrast agent bound to a targeting moiety on the biofilm via the targeting agent;
triggering at least one ablation laser pulse delivered at a wavelength and energy level sufficient to cause destruction of at least a portion of the bacterial cells within the biofilm;
monitoring a frequency of detection of a remaining portion of bacterial cells within the biofilm, and,
terminating when the frequency of detection of the remaining portion of bacterial cells within the biofilm falls below a threshold level.
10 . The method of claim 9 , wherein the at least one PA contrast agent is selected from the group consisting of: gold nanospheres, gold nanoshells, gold nanorods, gold cages, carbon nanoparticles, perfluorocarbon nanoparticles, carbon nanotubes, spectrally tunable golden carbon nanotubes, carbon nanohorns, magnetic nanoparticles, silica-coated magnetic nanoparticles, quantum dots, binary gold-carbon nanotube nanoparticles, multilayer nanoparticles, clustered nanoparticles, liposomes, micelles, and microbubbles.
11 . The method of claim 9 , wherein the at least one targeting agent comprises an antibody, a protein, a ligand for one or more specific cell receptors, a receptor, a peptide, or a wheat germ agglutinin.
12 . The method of claim 9 , wherein the at least one targeting agent is selected from the group consisting of antibodies to protein A receptors of Staphylococcus aureus , antibodies to a lipoprotein, ligands to polysaccharide and siderophore receptors of a bacteria, and an antibody specific for a protein highly expressed in the bacteria but absent in mammalian cells.
13 . The method of claim 12 , wherein the bacteria is chosen from: Clostridium difficile ; Carbapenem-resistant Enterobacteriaceae (CRE); drug-resistant Neisseria gonorrhoeae ; multidrug-resistant Acinetobacter ; drug-resistant Campylobacter ; extended spectrum β-lactamase producing Enterobacteriaceae (ESBLs); vancomycin-resistant Enterococcus (VRE); multidrug-resistant Pseudomonas aeruginosa ; drug-resistant non-typhoidal Salmonella ; drug-resistant Salmonella typhi ; drug-resistant Shigella ; methicillin-resistant Staphylococcus aureus (MRSA); drug-resistant Streptococcus pneumoniae ; drug-resistant tuberculosis; vancomycin-resistant Staphylococcus aureus (VRSA); erythromycin-resistant Group A Streptococcus ; clindamycin-resistant Group B Streptococcus; Staphylococcus epidermis ; and any combination thereof.
14 . The method of claim 10 , wherein the at least one detection laser pulse comprises a first wavelength used with a first PA contrast agent to detect the at least one bacteria cell and the at least one ablation laser pulse comprises a second wavelength used with a second PA contrast agent to destroy the at least one bacteria cell.
15 . The method of claim 9 , wherein the at least one functionalized PA contrast agent is contacted with the biofilm using injection at an injection site of the subject.
16 . A method for selectively destroying a biofilm within a subject in vivo, comprising:
contacting at least one functionalized PA contrast agent with the biofilm, wherein the at least one functionalized PA contrast agent comprises at least one PA contrast agent linked to at least one targeting agent; and,
triggering at least one pulse of laser energy delivered at a wavelength and energy level sufficient to cause destruction of the one or more bacterial cells, wherein the at least one functionalized contrast agent is bound to a targeting moiety on the biofilm via the targeting agent.
17 . The method of claim 16 , wherein the at least one PA contrast agent is selected from the group consisting of: gold nanospheres, gold nanoshells, gold nanorods, gold cages, carbon nanoparticles, perfluorocarbon nanoparticles, carbon nanotubes, spectrally tunable golden carbon nanotubes, carbon nanohorns, magnetic nanoparticles, silica-coated magnetic nanoparticles, quantum dots, binary gold-carbon nanotube nanoparticles, multilayer nanoparticles, clustered nanoparticles, liposomes, micelles, and microbubbles.
18 . The method of claim 16 , wherein the at least one targeting agent is selected from the group consisting of antibodies to protein A receptors of Staphylococcus aureus , antibodies to a lipoprotein, ligands to polysaccharide and siderophore receptors of a bacteria, and an antibody specific for a protein highly expressed in a bacteria but absent in mammalian cells.
19 . The method of claim 18 , wherein the bacteria is chosen from: Clostridium difficile ; Carbapenem-resistant Enterobacteriaceae (CRE); drug-resistant Neisseria gonorrhoeae ; multidrug-resistant Acinetobacter ; drug-resistant Campylobacter ; extended spectrum β-lactamase producing Enterobacteriaceae (ESBLs); vancomycin-resistant Enterococcus (VRE); multidrug-resistant Pseudomonas aeruginosa ; drug-resistant non-typhoidal Salmonella ; drug-resistant Salmonella typhi ; drug-resistant Shigella ; methicillin-resistant Staphylococcus aureus (MRSA); drug-resistant Streptococcus pneumoniae ; drug-resistant tuberculosis; vancomycin-resistant Staphylococcus aureus (VRSA); erythromycin-resistant Group A Streptococcus ; clindamycin-resistant Group B Streptococcus; Staphylococcus epidermis ; and any combination thereof.
20 . The method of claim 16 , wherein the at least one functionalized PA contrast agent is contacted with the biofilm using injection at an injection site of the subject.